Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To CMI add any stock that's Machinery Contracts Construction etc. Most had disappointing earnings, but WS has decided that just makes them cheap (DRC R ITW etc.).
APA OXY have been great, people went bearish near bottom, I guess the age old adage is true.
Thx for posting that XOP chart, I had missed that DT. Amazing how quickly the refiners jump back, TSO MPC VLO etc., while CVI still hitting highs.
XOP only +2.5% YTD now, how quickly a darling can turn to unwanted. Though, EPA probably a catalyst here.
Would love to see XEC at 65, would make for a nice round trip.
Enough is enough here, look forward to those ER's. CP also a nice railer.
IYT still +11.5% YTD, let's see if that remains the case
Many stocks coming off highs and hitting either 20MA or 50MA (or even both). Actually more than you'd expect given the lack of red days.
LVS really readily gave a lot back, even though not many days going by without Macau being mentioned :)
Yeah, always wait for the pullback to confirm it's pulling back :)
I only glanced over that derailment news for CP, didn't occur to me at the time then they'd use it to punish it hard.
What I gather most from the airlines, as posted on ST, is the fast they're definitely feeling the sequester cuts. I can't wait for ER season to hit.
If it does go back to $64, I bet there'll be a lot of people staring in disbelief. Amazing how fast this sometimes goes.
ASTM to stop enrollment, end Phase 3 REVIVE CLI study
-38% PM
Aastrom announces restructuring, to cut staff and operating expenses by 50%
Aastrom Biosciences announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy. Aastrom, which recently initiated the Phase 2b ixCELL-DCM clinical trial, previously received a U.S. orphan drug designation for the use of ixmyelocel-T in the treatment of DCM. As a result of the strategic change, Aastrom will stop enrollment and end the Phase 3 REVIVE clinical trial in patients with critical limb ischemia. In addition, the company is executing a corporate restructuring that will reduce staff and operating expenses by approximately 50%. The company stated: "We completed our strategic review of the CLI program, including an evaluation of the challenges in enrolling patients in the REVIVE study and a recent determination that the CLI program would not be supported by a partner in a timeframe that would impact the pace of enrollment of the study. Based on this review, we have decided that the best path to commercialization of ixmyelocel-T is to focus aggressively on the DCM program. We will begin treating patients in the Phase 2b ixCELL-DCM clinical study within the next few weeks. In our earlier Phase 2a DCM clinical trials, ixmyelocel-T was well-tolerated and efficacy observations were consistent with improved function of impaired myocardium in patients with DCM. In addition, preclinical results demonstrated that ixmyelocel-T was protective of ischemic heart tissue in a murine model of heart failure. These findings strongly support the decision to focus our resources on the development of ixmyelocel-T for the DCM orphan indication."
ZIOP tanker watch
It terminates development of palifosfamide & drops 58% in PM.
HALO: +30%
Search didn't find any post on the recent news for this one:
Halozyme Is Attractive Again After EU Opinion On HyQvia
Moved past the 50d/200d. has R at $7, but a jump to $8 seems doable.
Got my fingers crossed for KORS taking another ride down, that 100d is just too close not to be tested.
FDX, yeah, often best to leave the comment till after the entry, especially with narrow moves. Looks like it hit that December spike S, I did see it trying to bounce, but as you know had moved elsewhere. As commented, 97.03 was to be a difficult pivot point, and I turned out to be correct.
I'm loving AMZN under the 100d, though I do note the DB with the 3/19 close. 200d so close, magnet action may start.
Yeah, WYNN doesn't seem to be planning on losing that 50d again, speaks to its current strength. Careful watch.
ACAD flying
will always amaze me that people only know how to play long.
That's exactly why we have Bernanke.
Nice DB @ $98 for FOSL.
As for MOV, unless it's a really big beat and people decide time for a new range. Needs a 5% move to 39.12, that in itself is decent.
DE/FDX received little love, also watching CAT/JOY, they seem to be at a dangerous place. Same goes for OXY: I've noticed that several stocks, which have been hanging around MAs without moving much, are getting the stick as people tire of waiting. OXY hit that 78.50 S, let's see if that holds.
Nice MA sandwich on FSLR - also did the 100d @ 28.78 & 20 weekly @ 29.15), not bad for a day's move. Agree on the $31 target, though this one by no means trades logically.
Casino stocks, LVS & WYNN, woke up yesterday, think we had an analyst touting Macau growth. Not saying there's that much margin, but now that it's broken the 50d, perhaps revisit $126.
Saw your SPY move, nice déjà-vu play.
BBRY: only see MS upgrade to $22 PT.
WAG: tagged yesterday's 45.75
FDX: wonder if they'll ignore reality again and just push this up.
LEN bounced off 41.25 S, chart being respected. +1% or so, perhaps awaiting guidance, don't see any yet.
SPY past that R now.
BBRY upgraded to Overweight from Underweight at Morgan Stanley
Morgan Stanley upgraded BlackBerry two notches to Overweight from Underweight based on expanding gross margin and ASP expectations driven by the mix-shift to BB10 devices from BB6 and BB7 devices. The firm now believes there may be room for niche mid-range companies in the handset market and notes LG and Samsung may be seeking alternate OS strategies. Price target raised to $22 from $10.
LEN indeed a nice beat, should get XHB and SPY going.
Look forward to FDX, with that move YTD it's priced to deliver, or so I think.
Nice on WAC, let's see if it can bounce as hard.
CMI: every time it drops, analysts jump to the stage with upgrades. Think SPY sole shepherd in this type of stocks, as you've said.
Don't see any special BBRY news?
Gartner: Through 2016, BlackBerry to achieve under 5% smartphone market share
RNF was a bit tricky, gave you the impression it's all good before slowly fading. Would've liked 34.75 but can't get too picky :)
Yes, MOS top performer, POT more of a Jekyll/Hyde stock.
Watching stocks like HON/CVX/UPS to see how big the cracks are when we drop, so far they're holding. They keep pumping IYT, and so this is all noise till the real red.
Not easy to get 90%, agree, but for most not easy to either hold that long or wait that long. Or get out of the keep buying everything mentality.
Ah, the one with the jump on CEO news? I guess there is still some sense in this market, this was due to fall, just didn't deliver.
Good to hear you took the trip down, wonder how many longs are left scratching their heads.
Noted AGU is using $100 as S again, while CF took another trip down to the 2/26 close before bouncing.
REGN saw that, strong early action, as for CELG, longs shouldn't be too shocked, IMO, look at where we are compared to that small PB.
MNST seems to be doing the same waves time and again?
FSLR just won't die: reaching for the GF on the same day China lowers subsidies? Best I not over-think it.
LULU, you think they'll just keep it up here? Was liking this for far more of a pullback, must have die hard fans. Not even 3% lost yesterday.
KORS had more or less the same bounce as on the 13th, they did avoid retesting the 100d. Futures are looking green, surprise, so I doubt we get a test today.
WSM closed near that 47.80, makes sense looking at the chart.
WAG did do that breakout, but that one's special. And freaking BBY, that artificially pushed up balloon.
You mean pinky style? I hope not, was ugly enough as it is.
Some say overreaction, others see a reality change as it was the third straight quarter of slowing earnings growth for the company. Bit of a growth story ending and WS readjusting expectations and valuation.
When I take a gamble on a momentum stock I've never heard of, for which I have absolutely no S/R lines, I'm trading blind, and that means closing all windows that have no chart. From that point not losing a boatload of money takes precedence over sharing.
The stock popped up early on on one of my many FinViz scans, and was one of the top losers on any top 10 well before the put money making was over. I hardly uncovered a hidden gem.
http://finviz.com/screener.ashx?v=150&f=ind_stocksonly,sh_curvol_o50,sh_opt_option,sh_price_20to50,sh_relvol_o0.5,ta_changeopen_d3&ft=4&o=changeopen
WSM guides lower but is up because of placebo div raise and buyback? Meh.
ADBE FRAN also seem so so, easy to please 'investors' nowadays.